Dana Aftab Sells 48,383 Shares of Exelixis (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) EVP Dana Aftab sold 48,383 shares of the company’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $42.50, for a total value of $2,056,277.50. Following the completion of the transaction, the executive vice president directly owned 664,778 shares of the company’s stock, valued at approximately $28,253,065. The trade was a 6.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Exelixis Trading Down 1.7%

Shares of EXEL stock opened at $41.65 on Friday. The firm has a market capitalization of $11.17 billion, a price-to-earnings ratio of 20.02, a PEG ratio of 0.79 and a beta of 0.32. The business’s 50-day moving average price is $39.47 and its 200-day moving average price is $40.53. Exelixis, Inc. has a 12 month low of $31.90 and a 12 month high of $49.62.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.10. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The business had revenue of $597.76 million during the quarter, compared to analyst estimates of $590.04 million. During the same quarter last year, the business earned $0.47 EPS. The firm’s quarterly revenue was up 10.8% on a year-over-year basis. Exelixis has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of EXEL. Belpointe Asset Management LLC purchased a new stake in shares of Exelixis during the 1st quarter worth approximately $572,000. Fox Run Management L.L.C. bought a new position in Exelixis during the second quarter valued at $321,000. D.A. Davidson & CO. bought a new position in Exelixis during the second quarter valued at $212,000. Fortis Capital Advisors LLC purchased a new stake in Exelixis in the first quarter worth $572,000. Finally, Envestnet Asset Management Inc. raised its stake in shares of Exelixis by 23.9% in the first quarter. Envestnet Asset Management Inc. now owns 248,073 shares of the biotechnology company’s stock valued at $9,159,000 after buying an additional 47,845 shares during the period. Institutional investors and hedge funds own 85.27% of the company’s stock.

Analyst Ratings Changes

EXEL has been the subject of a number of recent research reports. Royal Bank Of Canada restated a “sector perform” rating and issued a $45.00 price objective on shares of Exelixis in a report on Tuesday, October 21st. Stifel Nicolaus set a $43.00 price objective on Exelixis in a research report on Wednesday, November 5th. HC Wainwright upped their target price on Exelixis from $46.00 to $49.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. William Blair restated an “outperform” rating on shares of Exelixis in a report on Tuesday, July 29th. Finally, Truist Financial reduced their price objective on shares of Exelixis from $56.00 to $49.00 and set a “buy” rating on the stock in a research note on Tuesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eleven have issued a Hold rating to the company. According to data from MarketBeat, Exelixis presently has an average rating of “Moderate Buy” and an average target price of $45.45.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.